Kutovyi V. Circulating antibodies and markers of inflammation in chronic heart failure: clinical significance and changes in the background of pharmacotherapy

Українська версія

Thesis for the degree of Candidate of Sciences (CSc)

State registration number

0412U006381

Applicant for

Specialization

  • 14.01.11 - Кардіологія

20-11-2012

Specialized Academic Board

Д 26.616.01

State Institution National Scientific Center "The M.D. Strazhesko Institute of Cardiology National Academy of Medical Sciences of Ukraine"

Essay

The work is devoted to the improvement of practical recommendations for the treatment of CHF due to AH and IHD based on assessment of the impact of various options of pharmacotherapy on the severity of myocardial damage, inflammation reaction and anemic syndrome by determining blood concentration of circulating antibodies to cardiac myosin, Hsp60, Hsp90, protein hBD-2, inflammation markers and anemia. An examination of 101 patients with CHF found that antibodies concentration depends on the patients' gender and age, the severity level of CHF, the heart rhythm nature, pharmacotherapy. The greatest reduction of the investigated antibodies, inflammation markers were observed in applying of the combination (ACEI, BAB, BRAII, D). The use of MRA in the combination (ACEI, BAB, D) contributed to more significant reduction of the antibodies concentration, inflammation markers.

Files

Similar theses